Estradiol, Vaginal

• Treatment of the genitourinary syndrome of menopause (vaginal atrophy, dryness, itching, and dyspareunia due to estrogen deficiency).
• May reduce recurrent urinary tract infections and some urinary symptoms in postmenopausal women when these are related to genitourinary atrophy.
• Preferred over systemic therapy when genitourinary symptoms are the only complaint, since systemic absorption and endometrial stimulation are minimal at recommended doses.
• An added progestogen is not required at recommended doses, even in women with an intact uterus.

Contraindicated in pregnancy. Confirm pregnancy status and discuss alternative therapy with the prescriber before dispensing.

• Contraindicated in known or suspected pregnancy.

• Not indicated in breastfeeding women; menopausal genitourinary atrophy is not the clinical context in which this product is used during lactation.

• No dose adjustment required based on age alone; this is the population in which the product is primarily used.

• Not indicated in patients under 18 years of age.

• Ring (Estring): insert 1 ring into the upper third of the vagina; leave in place continuously and replace every 3 months (90 days). The patient, or a healthcare professional if the patient prefers, can insert and remove the ring.
• Tablet (Vagifem 10): insert 1 tablet intravaginally using the supplied applicator once daily for the first 2 weeks, then reduce to twice weekly for maintenance.
• Use the lowest dose and shortest duration that controls symptoms, with periodic reassessment of ongoing need; unlike vasomotor symptoms, genitourinary syndrome of menopause typically does not improve on its own over time, so ongoing therapy is often needed for continued benefit.

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

• No clinically significant overdose scenario has been described at labelled local doses; if excessive product is used, manage symptomatically.

• Local burning, itching, or irritation at the application site may occur.
• Vaginal discharge or leakage may occur, particularly with the ring.
• Mild breast tenderness may occur, though this is much less common than with systemic estrogen.

Serious side effects require immediate discussion with the prescriber or emergency care.

• At recommended doses, systemic absorption is low and low-potency local vaginal estrogen has not been shown to increase the risk of endometrial hyperplasia in available trial data; endometrial safety data beyond 1 year of continuous use are more limited, though longer observational follow-up has not shown increased risk.
• Report any unexpected vaginal bleeding for evaluation, as with any estrogen-containing product.
• The class-level risks associated with systemic estrogen (blood clots, stroke, breast cancer) are not expected at labelled local doses but the product labelling still lists the same absolute contraindications out of caution.

• Vaginal infections or unhealed vaginal lesions should be addressed before or alongside starting therapy.
• In women using a latex diaphragm or latex condoms, note that some vaginal estrogen products can weaken latex; check the specific product's patient information.
• Personal history of breast cancer is listed as a contraindication on product labelling; current specialist guidance (North American Menopause Society, 2020 genitourinary syndrome of menopause position statement) supports individualized use of low-dose vaginal estrogen, with oncologist involvement, in patients whose genitourinary symptoms have not responded to non-hormonal measures — this decision should not be made unilaterally by a pharmacist or without documented oncology input.

• Known or suspected pregnancy.
• Undiagnosed abnormal vaginal bleeding.
• Known or suspected breast cancer or other estrogen-dependent cancer (per product labelling; see Use with caution for the individualized-exception context).
• Active liver disease.
• Active or past history of venous thromboembolism or arterial thromboembolic disease.
• Known hypersensitivity to estradiol or any component of the product.

• No clinically significant systemic drug interactions are expected at recommended local doses given minimal systemic absorption.
• Aromatase inhibitor therapy (used in some breast cancer regimens) is intended to suppress estrogen at the tissue level; combining it with any local estrogen product, including low-dose vaginal estradiol, has not been adequately studied and should only be considered with oncology input.

• None significant.

• Ring: inserted once and left in place continuously for 90 days, then replaced.
• Tablet: inserted at bedtime is common practice to minimize leakage, daily for 2 weeks then twice weekly thereafter.

• Store at room temperature; keep the ring in its original packaging until insertion.

• This is a low-dose, local treatment for vaginal dryness, irritation, and painful intercourse related to menopause — it works differently from, and carries a much lower systemic risk profile than, estrogen pills or patches.
• A second hormone (progestogen) is not needed with this product even if you still have a uterus, when used at the recommended dose.
• Report any new vaginal bleeding, and let your pharmacist or doctor know if you have a history of breast cancer before starting.
• Unlike hot flashes, vaginal dryness symptoms usually do not go away on their own, so ongoing use is often needed to keep symptoms controlled.